Keywords
To read this article in full you will need to make a payment
Purchase one-time access:
Academic & Personal: 24 hour online accessCorporate R&D Professionals: 24 hour online accessOne-time access price info
- For academic or personal research use, select 'Academic and Personal'
- For corporate R&D use, select 'Corporate R&D Professionals'
Subscribe:
Subscribe to Advances in OncologyAlready a print subscriber? Claim online access
Already an online subscriber? Sign in
Register: Create an account
Institutional Access: Sign in to ScienceDirect
References
- Key Statistics for Endometrial Cancer.(Available at:)
- Endometrial Cancer: Is This a New Disease?.Am Soc Clin Oncol Educ Book. 2017; : 435-442
- Gynecologic Oncology Group. A phase III trial of surgery with or without adjunctive external pelvic radiation therapy in intermediate risk endometrial adenocarcinoma: a Gynecologic Oncology Group study.Gynecol Oncol. 2004; 92 (Erratum in: Gynecol Oncol. 2004;94(1):241-751.): 744-751
- Surgery and postoperative radiotherapy versus surgery alone for patients with stage-1 endometrial carcinoma: multicentre randomised trial. PORTEC Study Group. Post Operative Radiation Therapy in Endometrial Carcinoma.Lancet. 2000; 355: 1404-1411
- Phase III Trial: Adjuvant Pelvic Radiation Therapy Versus Vaginal Brachytherapy Plus Paclitaxel/Carboplatin in High-Intermediate and High-Risk Early Stage Endometrial Cancer.J Clin Oncol. 2019; 37: 1810-1818
- Adjuvant chemoradiotherapy versus radiotherapy alone for women with high¬ risk endometrial cancer (PORTEC-3): final results of an international, open¬label, multicentre, randomised, phase 3 trial.Lancet Oncol. 2018; 19: 295-309
- Adjuvant chemotherapy plus radiation for locally advanced endometrial cancer.N Engl J Med. 2019; 380: 2317e2326
- Surgical pathologic spread patterns of endometrial cancer. A Gynecologic Oncology Group Study.Cancer. 1987; 60: 2035-2041
- Vaginal brachytherapy versus pelvic external beam radiotherapy for patients with endometrial cancer of high-intermediate risk (PORTEC-2): an open-label, non-inferiority, randomised trial.Lancet. 2010; 375: 816-823
- Substantial lymph-vascular space invasion (LVSI) is a significant risk factor for recurrence in endometrial cancer--A pooled analysis of PORTEC 1 and 2 trials.Eur J Cancer. 2015; 51: 1742-1750
- Ten-year outcome including patterns of failure and toxicity for adjuvant whole abdominopelvic irradiation in high-risk and poor histologic feature patients with endometrial carcinoma.Int J Radiat Oncol Biol Phys. 2002; 54: 527-535
- Randomized Phase III Trial of Whole-Abdominal Irradiation Versus Doxorubicin and Cisplatin Chemotherapy in Advanced Endometrial Carcinoma: A Gynecologic Oncology Group Study.J Clin Oncol. 2006; 24: 36-44
- Adjuvant chemotherapy vs radiotherapy in high-risk endometrial carcinoma: results of a randomised trial.Br J Cancer. 2006; 95: 266-271
- Randomized phase III trial of pelvic radiotherapy versus cisplatin based combined chemotherapy in patients with intermediate and high risk endometrial cancer: a Japanese Gynecologic Oncology Group study.Gynecol Oncol. 2008; 108: 22633
- Final analysis of RTOG 9708: Adjuvant postoperative irradiation combined with cisplatin/paclitaxel chemotherapy following surgery for patients with high-risk endometrial cancer.Gynecol Oncol. 2006; 103: 155-159
- Impact of intensity-modulated radiotherapy on acute hematologic toxicity in women with gynecologic malignancies.Int J Radiat Oncol Biol Phys. 2002; 54: 1388-1396
- Intensity-modulated whole pelvic radiation therapy in patients with gynecologic malignancies.Int J Radiat Oncol Biol Phys. 2000; 48: 1613-1621
- Intensity-modulated radiation therapy in gynecologic malignancies.Med Dosim. 2002; 27: 131-136
- Incorporation of SPECT bone marrow imaging into intensity modulated whole-pelvic radiation therapy treatment planning for gynecologic malignancies.Radiother Oncol. 2005; 77: 11-17
- IMRT Improves Late Toxicity Compared to Conventional RT: An Update on NRG Oncology-RTOG 1203.Int J Radiat Oncol Biol Phys. 2019; 105: S50https://doi.org/10.1016/j.ijrobp.2019.06.480
- Hematologic toxicity in RTOG 0418: a phase 2 study of postoperative IMRT for gynecologic cancer.Int J Radiat Oncol Biol Phys. 2013; 86: 83-90
- Patient-Reported Toxicity During Pelvic Intensity-Modulated Radiation Therapy: NRG Oncology-RTOG 1203.J Clin Oncol. 2018; 36 (Epub 2018 Jul 10. Erratum in: J Clin Oncol. 2019 Mar 20;37(9):761. Erratum in: J Clin Oncol. 2020 Apr 1;38(10):1118. PMID: 29989857; PMCID: PMC6097832): 2538-2544
- Improvement in Patient-Reported Outcomes With Intensity-Modulated Radiotherapy (RT) Compared With Standard RT: A Report From the NRG Oncology RTOG 1203 Study.J Clin Oncol. 2020; 38 (Epub 2020 Feb 19. PMID: 32073955; PMCID: PMC7238486): 1685-1692
- Phase III Randomized Trial of Postoperative Adjuvant Conventional Radiation (3DCRT) versus Image Guided Intensity Modulated Radiotherapy (IG-IMRT) in Cervical Cancer (PARCER): Final Analysis.Int J Radiat Oncol Biol Phys. 2020; 108: S1
- Adjuvant chemoradiotherapy versus radiotherapy alone in women with high-risk endometrial cancer (PORTEC-3): patterns of recurrence and post-hoc survival analysis of a randomised phase 3 trial.Lancet Oncol. 2019; 20 (Epub 2019 Jul 22. Erratum in: Lancet Oncol. 2019 Sep;20(9):e468. PMID: 31345626; PMCID: PMC6722042.): 1273-1285
- A Multi-Institutional Analysis of Adjuvant Chemotherapy and Radiation Sequence in Women With Stage IIIC Endometrial Cancer.Int J Radiat Oncol Biol Phys. 2021; 110: 1423-1431
- Postoperative External Irradiation and Prognostic Parameters in Stage I Endometrial Carcinoma: Clinical and Histopathologic Study of 540 Patients.Obstet Gynecol. 1980; 56: 419-427
- Multi-institutional Analysis of Vaginal Brachytherapy Alone for Women With Stage II Endometrial Carcinoma.Int J Radiat Oncol Biol Phys. 2018; 101: 1069-1077
- Integrated genomic characterization of endometrial carcinoma.Nature. 2013; 497 (Erratum in: Nature. 2013;500(7461):242): 67-73
- Molecular Classification of the PORTEC-3 Trial for High-Risk Endometrial Cancer: Impact on Prognosis and Benefit From Adjuvant Therapy.J Clin Oncol. 2020; 38: 3388-3397
- PORTEC-4a: international randomized trial of molecular profile-based adjuvant treatment for women with high-intermediate risk endometrial cancer.Int J Gynecol Cancer. 2020; 30: 2002-2007
Article info
Identification
Copyright
© 2022 Elsevier Inc. All rights reserved.
